Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Joe Copia who wrote (9679)	11/7/1998 1:28:00 AM
From: DavidCG	Respond to of 25711

The next GERN or ENMD? AVIIW and AVII in Phase III human trials $1.50 and $4 AVII : gene therapy/vaccines/antisense for cancer.. Phase III human testing for one cancer (colorectal (colon) cancer) about to begin with 300 patients. Phase II human testing for two other cancer vaccines. (prostate and pancreatic). Phase I human testing for two other antisense cancer drugs. One Drug delivery technology with potential for MANY drugs. Currently in FIVE clinical human studies. AVII has over 27 patents! Of those..look at this one: "This basket of technology includes one issued patent and one provisional patent application describing the use of telomere mimics for the treatment of cancer and other diseases. Telomeres are DNA sequences on the ends of chromosomes that define the age of a cell. Cancer cells are ageless or immortal due to their ability to reset the telomere-aging clock. This synthetic oligonucleotide strategy interferes with the system of communication between the telomere and the aging process in cancer cells, resulting in rapid and selective cancer cell death. The telomere communication system may also be involved in a variety of chronic diseases including rheumatoid arthritis." Remind you of GERN? ENMD? Antisense, Gene Therapy, Cancer Vaccines, Drug delivery, Telomeres All wrapped into one company trading at a fraction of where it should be? antivirals.com Trading at $4.00 a share, Only 11 mil Outstanding, and 6.3 mil float. -DavidCG AVI BioPharma Inc. is dedicated to the development and commercialization of products for the treatment of life-threatening diseases using three platform technologies: immunotherapy for cancer, gene-targeted drugs and intracellular drug delivery engines. Its lead clinical agent, Avicine(tm), an essentially non-toxic cancer vaccine, will soon enter a Phase III licensing trial in colorectal cancer, a Phase II/III trial in pancreatic cancer and a Phase II trial in prostate cancer. The Company has also developed a patented class of gene-targeted drugs, called NeuGenes(R), which may be useful in the treatment of a wide range of human diseases including cardiovascular restenosis and cancer. Further, AVI has developed a novel drug delivery technology, called CytoPorter(tm), that may be useful in significantly improving drug uptake while minimizing toxicity for a wide range of FDA approved drugs.

To: Joe Copia who wrote (9679)	11/7/1998 8:31:00 AM
From: John Crovelli	Respond to of 25711

Joe, beaten down GRNO comes back to life: Friday November 6, 4:47 pm Eastern Time Company Press Release SOURCE: Green Oasis Environmental, Inc. Green Oasis Environmental, Inc. (GOE, Inc.) Secures Asian Joint-Venture Partner CHARLESTON, S.C., Nov. 6 /PRNewswire/ -- Green Oasis Environmental, Inc. (OTC Bulletin Board: GRNO - news) announced today the formation of a China corporation, Green Oasis Environmental Qingdao Co., Ltd.(the joint venture company) which will be owned 50% by Green Oasis Environmental, Inc., and 50% by Qingdao Asia-Pacific Benz Motorcar Co., LTD. (China PARTNER) based in Qingdao, China. The China Partner will purchase a total of 1 million shares of Green Oasis Series B convertible preferred stock ( $1.00 par value) for $ 1.00 per share, of which the first investment trounch of $100,000 has occurred. The China Partner will purchase the additional 900,000 shares as follows: December 1998, 100,000 shares, January 1999, 100,000 shares, March 1999, 200,000 shares, April 1999, 500,000 shares. In addition the China Partner will capitalize the joint-venture company with not less than $ 3 million US dollars. The joint-venture company has optioned an 8.2 acre site in the Qingdao Hightech Industrial Park which adjoins Hewlett Packard and Lucent Technologies for the construction of an office building, plant manufacturing facilities, tank farm and waste oil processing center to accommodate two model 1000 plants of 60,000 square feet, worker and management housing, and visitor bungalow. The joint-venture company will be the exclusive marketing agent for China and the exclusive plant manufacturing agent for Asia. Green Oasis retains the responsibility for plant installation, customer training, and plant start-up. The target date for the joint-ventures' first model 1000 plant to be operational in Qingdao, China is June 1999. Qingdao Asia-Pacific Benz Motorcar Co., Ltd.'s existing relationship with General Motors, Ford and Chrysler complement the US relationship now formed with Green Oasis. The joint-venture is scheduled to serve as host to the Environmental Protection Agency of the People's Republic of China's National Environmental Conference in Qingdao, China. Mr. Yanging Zhow, Chairman of Qingdao Asia-Pacific Benz Motorcar Co., Ltd. will serve as Chairman of the Board of Directors of the joint-venture company which will have six Directors, three from each company. W. D. Carraway, President of GOE, Inc. stated, without the efforts of Charleston based United States Investment Alliance, and their partners and relationships in China, this opportunity would not have been possible. We believe Qingdao Asia-Pacific Benz Motorcar Co., Ltd. is the ideal partner because they understand the waste oil market in China and the financial opportunities associated with a product, diesel fuel, that is currently selling for 71 cents a liter. Green Oasis continues to move its technology and business forward as noted; June 1998, the EPA classification of GOE's diesel fuel product as a synthetic alternative fuel; July 1998, DHE, South Carolina, issued the necessary permits required to modify and operate the Charleston plant at a capacity of 1000 gallons per hour; August 1998, the consent settlement by GOE, Inc., respecting all of its issues with the SEC was confirmed by Court Order; September 1998, the United States Department of Commerce Patent and Trademark office issued the process patent, and now the joint-venture Asian relationship and equity capital investment in Green Oasis. Green Oasis' patented process is designed to produce marketable fuels from waste oils in a closed cycle, one step process. The Company manufactures equipment for its own use as well as markets worldwide. For Additional Information Contact: William D. Carraway, President Green Oasis Environmental, Inc. Charleston, SC 843-722-5771 E-Mail: grno@awod.com SOURCE: Green Oasis Environmental, Inc.